Constructive cigarette regulation.

Duke Law J

Harvard Law School, USA.

Published: April 1998

Professor W. Kip Viscusi argues for a move away from the adversarial approach to tobacco regulation, an approach that is currently embodied in class action lawsuits and the proposed broadening of FDA regulatory power over cigarettes. In this Article, he suggests that the FDA should take a constructive role in fostering technological innovations to promote cigarette safety, in much the same way that the government currently fosters safety improvements in motor vehicles and jobs. Professor Viscusi claims that the objective of government policy should be to promote informed consumer risk taking--an approach which recognizes that adult consumers have a right to smoke and to incur the associated risks. He provides survey data demonstrating that although consumers know that smoking is a risky decision, they have little exposure to information regarding the comparative riskiness of various cigarette brands. According to Professor Viscusi, the government should assist in compiling and disseminating information regarding the comparative risks of different smoking options and the effects of certain innovative safety features for cigarettes. Making this information available would enable consumers to make more informed smoking decisions and potentially minimize the health hazards that smoking poses.

Download full-text PDF

Source

Publication Analysis

Top Keywords

professor viscusi
8
constructive cigarette
4
cigarette regulation
4
regulation professor
4
professor kip
4
kip viscusi
4
viscusi argues
4
argues move
4
move adversarial
4
adversarial approach
4

Similar Publications

The global COVID-19 mortality cost report card: 2020, 2021, and 2022.

PLoS One

May 2023

University Distinguished Professor of Law, Economics, and Management, Vanderbilt University, Nashville, TN, United States of America.

The United States is the country with the greatest number of COVID-19 deaths in 2020, 2021, and 2022. Both the U.S.

View Article and Find Full Text PDF

Risk-Risk Tradeoffs for Mass Shootings and International Terrorism.

Risk Anal

December 2021

University Distinguished Professor of Law, Economics, and Management, Vanderbilt Law School, 131 21st Ave. South, Nashville, TN, USA.

This article elicits information about risk perceptions and risk-risk tradeoffs for mass shootings and international terrorist attacks. These prominent public risks are similar in many respects in that both involve traumatic injuries. One might expect that the risk-risk tradeoff rate would be 1.

View Article and Find Full Text PDF

The COVID-19 pandemic poses novel health issues. However, the benefits and costs of the pandemic and policies to address it have a familiar economic structure. Chief among the health-related benefits are the monetized values of the U.

View Article and Find Full Text PDF

The impact of cannabis access laws on opioid prescribing.

J Health Econ

January 2020

University Distinguished Professor of Law, Economics, and Management, Vanderbilt University Law School. 131 21st Avenue South, Nashville, TN, 37203, United States. Electronic address:

While recent research has shown that cannabis access laws can reduce the use of prescription opioids, the effect of these laws on opioid use is not well understood for all dimensions of use and for the general United States population. Analyzing a dataset of over 1.5 billion individual opioid prescriptions between 2011 and 2018, which were aggregated to the individual provider-year level, we find that recreational and medical cannabis access laws reduce the number of morphine milligram equivalents prescribed each year by 11.

View Article and Find Full Text PDF

Background And Objectives: Acute postoperative pain management in the geriatric patient can be challenging, including their response to medications. The purpose of this analysis was to evaluate whether the efficacy and safety profile of fentanyl iontophoretic transdermal system (ITS) (IONSYS) was similar in geriatric (≥65 years) and non-geriatric (<65 years) patients.

Methods: Efficacy and safety data from three randomized, double-blind, placebo-controlled trials and four randomized, open-label, active-comparator trials were utilized for this analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!